• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Anti-Cancer Therapeutics - Articles and news items

gastric cancer treatment

Gastric cancer treatment development shifting to mAbs

Industry news / 17 March 2016 / Victoria White

The dominance of small molecules in the gastric cancer treatment space could be about to give way to monoclonal antibodies, according to GBI Research…

The Comet Assay – A valuable tool for Cancer Research (Feature image)

The Comet Assay – A valuable tool for Cancer Research

Webinars / 6 January 2016 /

This webinar presents real-world methods and examples of how to monitor and assess DNA damage in these cells using the Comet Assay and an insight into the software used to carry out this analysis – Komet…

TPI 287

Updated results from Phase 1/2 clinical trial evaluating TPI 287 for treatment of recurrent glioblastoma announced

Industry news / 22 April 2015 / Victoria White

Cortice Biosciences has announced interim results a Phase 1/2 trial evaluating TPI 287 plus bevacizumab for the treatment of glioblastoma multiforme…

mesothelioma

Early findings from KEYTRUDA trial in advanced pleural mesothelioma presented at AACR 2015

Industry news / 20 April 2015 / Victoria White

The first presentation of data investigating the use of KEYTRUDA in 25 patients with advanced pleural mesothelioma was made at AACR 2015…

umc utrecht

UMC Utrecht’s new liver cancer treatment approved for use in Europe

Industry news / 14 April 2015 / Victoria White

A new liver cancer treatment developed by the UMC Utrecht that uses uses radioactive holmium microspheres has received the European CE mark…

dna-immunotherapy

Inovio’s INO-3112 DNA immunotherapy shows positive preliminary results

Industry news / 9 April 2015 / Victoria White

INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)…

Exelixis

Exelixis’ cabozantinib granted Fast Track designation by FDA for advanced renal cell carcinoma

Industry news / 9 April 2015 / Victoria White

Exelixis has announced that the FDA has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma…

advaxis

Advaxis and Merck announce initiation of enrollment in the Phase 1/2 study of ADXS-PSA in combination with KEYTRUDA®

Industry news / 8 April 2015 / Victoria White

Advaxis and Merck have initiated enrollment in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA and KEYTRUDA in patients with mCRPC…

dna immunotherapy

Lion Biotechnologies announces publication of data from clinical study of metastatic cervical cancer patients treated with HPV-TIL

Industry news, Uncategorized / 8 April 2015 / Victoria White

Lion Biotechnologies has announced that data from a study of metastatic cervical cancer patients treated with treated with HPV-TIL has been published…

cell therapy

Apceth initiates Phase II clinical trial for pioneering engineered cell therapy to treat gastrointestinal cancer

Industry news / 26 March 2015 / Victoria White

Apceth has announced the successful completion of the Phase I and initiation of the Phase II with the engineered cell therapy product Agenmestencel-T…

TandAbs-feature

TandAbs: potent and well-manufacturable bi-specific antibodies for immunooncology

Issue 1 2015 / 10 March 2015 / Michael Weichel, Kristina Ellwanger, Ivica Fucek, Stefan H.J. Knackmuss, Erich Rajkovic, Uwe Reusch, Claudia Wall, and Eugene A. Zhukovsky, Affimed Therapeutics AG

The bi-specific antibody format is becoming the preferred antibody modality for current development projects in the pharmaceutical industry. This is due to an unsurpassed increase in functional activity relative to traditional mono-specific monoclonal antibodies, and a breakthrough in manufacturability enabled by novel designs. One such bi-specific format, the TandAb, produces antibodies that potently recruit immune effector cells to kill tumour cells, and TandAb antibodies are currently undergoing clinical trials for the treatment of hematological malignancies. Here we describe the selection process for the identification of stable and functional TandAbs and their manufacturability…

Paul Wituschek, Catalent

Antibody Drug Conjugates (ADC)

Supplier news / 19 February 2014 / Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent

Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: “Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?”

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +